Abbvie's Phase III trial of Humira meets primary endpoint

AbbVie has reported positive results from a Phase III pivotal trial, which was designed to evaluate the investigational use of Humira (adalimumab) in patients with moderate-to-severe hidradenitis suppurativa (HS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news